황반변성 치료 시장 규모, 점유율, 성장 분석 : 유형별, 치료법별, 질병 단계별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)

Global Macular Degeneration Treatment Market size was valued at USD 18.12 Billion in 2024 and is poised to grow from USD 19.66 Billion in 2025 to USD 37.76 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global macular degeneration treatment market is experiencing rapid growth, driven by the increasing prevalence of age-related macular degeneration (AMD) and an aging population. This sector focuses on enhancing patient quality of life by addressing significant unmet medical needs. Key growth drivers include advancements in treatment technologies like anti-vascular endothelial growth factor (anti-VEGF) therapies and sustained-release drug delivery systems, which improve outcomes for patients. Additionally, heightened awareness of early detection boosts demand for effective therapies. However, obstacles such as high treatment costs and regulatory challenges persist. Noteworthy trends involve the rise of combination therapies that effectively target multiple disease pathways and emerging gene therapy approaches. Significant opportunities lie within untapped markets, particularly in regions like Asia-Pacific and Latin America, supported by advancements in AI and machine learning for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segments Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As this condition predominantly impacts individuals over 50, the increasing number of older adults worldwide is anticipated to lead to a higher incidence of macular degeneration. With the global demographic trends indicating a substantial rise in the elderly population, the demand for effective treatments is expected to surge. This shift emphasizes the need for innovative therapeutic options to address the challenges posed by age-related macular degeneration, thereby driving market growth and encouraging advancements in treatment methodologies and healthcare solutions tailored to this demographic.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces significant challenges due to stringent regulatory requirements and protracted approval processes for new therapies. The development of innovative treatment options necessitates extensive clinical trials, thorough safety assessments, and comprehensive regulatory submissions, all of which can be both time-consuming and financially burdensome. This complicated regulatory landscape may discourage some pharmaceutical companies from pursuing research and development in this area, ultimately restricting the introduction of novel treatments into the market. Consequently, the slow progression of new therapies can hinder patient access to advanced care options for macular degeneration.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have transformed patient care dynamics. This trend facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person appointments. By leveraging home-based visual acuity tests and smartphone imaging devices, healthcare providers can ensure timely interventions and better disease management, ultimately enhancing patient convenience and optimizing healthcare costs. This shift towards digital solutions is indicative of evolving healthcare practices, underscoring a commitment to improving patient outcomes while streamlining treatment protocols in the macular degeneration landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2026-2033)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations